---
product_id: 7931048
title: "Surviving \"Terminal\" Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About"
price: "$56.18"
currency: USD
in_stock: true
reviews_count: 10
url: https://www.desertcart.us/products/7931048-surviving-terminal-cancer-clinical-trials-drug-cocktails-and-other-treatments
store_origin: US
region: United States of America
---

# Surviving "Terminal" Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About

**Price:** $56.18
**Availability:** ✅ In Stock

## Quick Answers

- **What is this?** Surviving "Terminal" Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About
- **How much does it cost?** $56.18 with free shipping
- **Is it available?** Yes, in stock and ready to ship
- **Where can I buy it?** [www.desertcart.us](https://www.desertcart.us/products/7931048-surviving-terminal-cancer-clinical-trials-drug-cocktails-and-other-treatments)

## Best For

- Customers looking for quality international products

## Why This Product

- Free international shipping included
- Worldwide delivery with tracking
- 15-day hassle-free returns

## Description

Surviving Terminal Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About [Williams Ph.D., Ben A.] on desertcart.com. *FREE* shipping on qualifying offers. Surviving Terminal Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About

Review: Very interesting and informative - A critical perspective of the cancer industry from a very intelligent patient. Good for thought of you ever have to deal with cancer.
Review: 12 Year Survivor of a 2 Year Disease - The Gold Standard treatment for Glioblastoma Multiforme (GBM) brain tumors is a combination of surgery, radiation and the chemotherapy themozolomide (Temodar / Temodal). Untreated, GBM uniformly kills its victims within four months. For 10% of all patients treated with radiation, that survival expectation increases to two years. At four years, 3% of the original group will still be alive. Add Temodar and surgery to that radiation, and 27% of those treated can expect to survive to two years. At four years, 12% of those treated with the Gold Standard combination will still be alive. University study press releases cheer the dramatic increase in surivival rates for patients receiving Tamodar along with radiation and surgery. From 10% to 27% for two years and from 3% to 12% for four years are big jumps. While the numbers do represent a significant increase, the fact remains that at four years, 88% of those receiving the Gold Standard treatment for Glioblastoma Multiforme tumors will be dead. In 1995, before Temodar was anywhere near the marketplace, Dr. Ben Williams discovered that he had a large Glioblastoma Multiforme tumor. Williams looked at the survival rates for those receiving the recommended treatment and did not like the odds. A research scientist and academic, Williams scoured every resource to create a state-of-the-art Glioblastoma Multiforme protocol. He received all of the standard treatment, which he supplemented with six other anti-cancer, pro-immune agents (and aspirin for the side effects). Williams combined the prescribed treatment: * Surgery (which left mass behind) * Radiation * BCNU chemotherapy * PCV chemotherapy With these addition of these agents: * Tamoxifen * Verapamil * Accutane * Melatonin * Mushroom extract * Gamma Linolenic Acid * Aspirin The treatment the oncologist recommended was certain to result in Williams' death. Yet the doctor refused any treatment outside the standard protocol, for fear of doing harm. Williams believed that nothing was more harmful than death. The oncologist only budged a little. He gave Williams some Tamoxifen. Everything else Williams took to reduce his tumor - including a higher dose of Tamoxifen than the oncologist would prescribe -- he researched and obtained on his own. A 1995 Gold Standard for GBM tumor treatment did not exist. The oncologist offered surgery, radiation and chemotherapy. The difference between 1995 and 2007 is the accuracy of the radiation and the quality of the chemotherapy. At two years from diagnosis - when 92% of patients receiving standard treatment would be dead - Williams received the first of what is now 12 years of clean MRIs. Williams regards his low-toxicity drug cocktail as a synergistic weapon against glioblastoma multiforme. He compares the current Gold Standard GBM treatment to the AZT AIDS treatment. Although AZT worked at first, the body developed a resistance to it. No more HIV patients were alive at four years on AZT than off of it. GBM cancer cells also adapt to chemotherapy. They're not adept at adapting to the low-toxicity cocktail Williams invented. The Accutane prevented the cancer cells from consuming the cells nearby. The Tamoxifen slowed the cancer cells' ability to extrude out the chemotherapy. The Gamma-Linolenic Acid produced free radicals inside the tumor, killing it from the inside out. As a rule, oncologists do not offer these treatments to brain tumor patients. These treatments are not "proven." If the FDA (Food and Drug Administration) has not blessed the substance then the doctor will not prescribe it, even if the doctor's treatment itself means almost certain death. Doctors know, says Williams, that their patients will die. So what is the problem prescribing low-toxicity agents that might cure brain tumors? Going outside the system can have a dramatically negative affect on a doctor's career. He might be accused of fraud, profiteering or incompetence. In a profession based on the credo "First, do no harm," doctors would first like to do no harm to their own careers. Doctors find themselves trapped between the FDA and the medical self-policing infra-structure on the one hand, and certain death for their patients on the other. Doctors won't prescribe the cocktail agents Williams took because they are not "proven" according to FDA standards. The approval process requires billions of dollars. Pharmaceutical companies won't research drugs that will not be economically viable. The drug must be exclusive to the pharmaceutical company. The population requiring the drug must be large enough to expect a return on investment. Many of the agents Williams used to cure his cancer are not patentable. Competitors would be able to copy and sell the compound. About 12,000 people a year are diagnosed with glioblastoma multiforme tumors. The market is not large enough to justify very expensive scientific trials. Beaten down by disease, radiation and chemotherapy, few GBM patients have the energy to climb the hurdles to promising but not "proven" treatments. Even when the outcome is certain death patients who ask for more will not receive it. Just as AIDS patients created political pressure to get "unproven" treatments for HIV, Williams encourages GBM patients to insist on access to "unproven" treatments for GBM. Dispensing only "proven" treatment is legal, says Williams. But denying dying patients access to substances that could save their lives is grossly unethical. Already fighting the deadliest of brain tumors, patients should not have to fight for promising but "unproven" cures. Until the political pressure on the FDA reaches a critical mass, he says, the GBM Gold Standard Treatment will still produce a four year death rate of 88%. [...]

## Technical Specifications

| Specification | Value |
|---------------|-------|
| Best Sellers Rank | #336,701 in Books ( See Top 100 in Books ) #155 in Oncology (Books) |
| Customer Reviews | 4.6 4.6 out of 5 stars (278) |
| Dimensions  | 7 x 0.65 x 10 inches |
| Edition  | 1st |
| ISBN-10  | 1477496513 |
| ISBN-13  | 978-1477496510 |
| Item Weight  | 1.35 pounds |
| Language  | English |
| Print length  | 288 pages |
| Publication date  | June 2, 2002 |
| Publisher  | CreateSpace Independent Publishing Platform |

## Images

![Surviving "Terminal" Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About - Image 1](https://m.media-amazon.com/images/I/61e6PF2i0nL.jpg)

## Customer Reviews

### ⭐⭐⭐⭐⭐ Very interesting and informative
*by J***S on April 2, 2025*

A critical perspective of the cancer industry from a very intelligent patient. Good for thought of you ever have to deal with cancer.

### ⭐⭐⭐⭐⭐ 12 Year Survivor of a 2 Year Disease
*by C***E on November 5, 2007*

The Gold Standard treatment for Glioblastoma Multiforme (GBM) brain tumors is a combination of surgery, radiation and the chemotherapy themozolomide (Temodar / Temodal). Untreated, GBM uniformly kills its victims within four months. For 10% of all patients treated with radiation, that survival expectation increases to two years. At four years, 3% of the original group will still be alive. Add Temodar and surgery to that radiation, and 27% of those treated can expect to survive to two years. At four years, 12% of those treated with the Gold Standard combination will still be alive. University study press releases cheer the dramatic increase in surivival rates for patients receiving Tamodar along with radiation and surgery. From 10% to 27% for two years and from 3% to 12% for four years are big jumps. While the numbers do represent a significant increase, the fact remains that at four years, 88% of those receiving the Gold Standard treatment for Glioblastoma Multiforme tumors will be dead. In 1995, before Temodar was anywhere near the marketplace, Dr. Ben Williams discovered that he had a large Glioblastoma Multiforme tumor. Williams looked at the survival rates for those receiving the recommended treatment and did not like the odds. A research scientist and academic, Williams scoured every resource to create a state-of-the-art Glioblastoma Multiforme protocol. He received all of the standard treatment, which he supplemented with six other anti-cancer, pro-immune agents (and aspirin for the side effects). Williams combined the prescribed treatment: * Surgery (which left mass behind) * Radiation * BCNU chemotherapy * PCV chemotherapy With these addition of these agents: * Tamoxifen * Verapamil * Accutane * Melatonin * Mushroom extract * Gamma Linolenic Acid * Aspirin The treatment the oncologist recommended was certain to result in Williams' death. Yet the doctor refused any treatment outside the standard protocol, for fear of doing harm. Williams believed that nothing was more harmful than death. The oncologist only budged a little. He gave Williams some Tamoxifen. Everything else Williams took to reduce his tumor - including a higher dose of Tamoxifen than the oncologist would prescribe -- he researched and obtained on his own. A 1995 Gold Standard for GBM tumor treatment did not exist. The oncologist offered surgery, radiation and chemotherapy. The difference between 1995 and 2007 is the accuracy of the radiation and the quality of the chemotherapy. At two years from diagnosis - when 92% of patients receiving standard treatment would be dead - Williams received the first of what is now 12 years of clean MRIs. Williams regards his low-toxicity drug cocktail as a synergistic weapon against glioblastoma multiforme. He compares the current Gold Standard GBM treatment to the AZT AIDS treatment. Although AZT worked at first, the body developed a resistance to it. No more HIV patients were alive at four years on AZT than off of it. GBM cancer cells also adapt to chemotherapy. They're not adept at adapting to the low-toxicity cocktail Williams invented. The Accutane prevented the cancer cells from consuming the cells nearby. The Tamoxifen slowed the cancer cells' ability to extrude out the chemotherapy. The Gamma-Linolenic Acid produced free radicals inside the tumor, killing it from the inside out. As a rule, oncologists do not offer these treatments to brain tumor patients. These treatments are not "proven." If the FDA (Food and Drug Administration) has not blessed the substance then the doctor will not prescribe it, even if the doctor's treatment itself means almost certain death. Doctors know, says Williams, that their patients will die. So what is the problem prescribing low-toxicity agents that might cure brain tumors? Going outside the system can have a dramatically negative affect on a doctor's career. He might be accused of fraud, profiteering or incompetence. In a profession based on the credo "First, do no harm," doctors would first like to do no harm to their own careers. Doctors find themselves trapped between the FDA and the medical self-policing infra-structure on the one hand, and certain death for their patients on the other. Doctors won't prescribe the cocktail agents Williams took because they are not "proven" according to FDA standards. The approval process requires billions of dollars. Pharmaceutical companies won't research drugs that will not be economically viable. The drug must be exclusive to the pharmaceutical company. The population requiring the drug must be large enough to expect a return on investment. Many of the agents Williams used to cure his cancer are not patentable. Competitors would be able to copy and sell the compound. About 12,000 people a year are diagnosed with glioblastoma multiforme tumors. The market is not large enough to justify very expensive scientific trials. Beaten down by disease, radiation and chemotherapy, few GBM patients have the energy to climb the hurdles to promising but not "proven" treatments. Even when the outcome is certain death patients who ask for more will not receive it. Just as AIDS patients created political pressure to get "unproven" treatments for HIV, Williams encourages GBM patients to insist on access to "unproven" treatments for GBM. Dispensing only "proven" treatment is legal, says Williams. But denying dying patients access to substances that could save their lives is grossly unethical. Already fighting the deadliest of brain tumors, patients should not have to fight for promising but "unproven" cures. Until the political pressure on the FDA reaches a critical mass, he says, the GBM Gold Standard Treatment will still produce a four year death rate of 88%. [...]

### ⭐⭐⭐⭐⭐ Inspiring Narrative
*by N***N on July 27, 2017*

A fantastic book, written by a learned author who negotiated the maze of brain cancer treatments--both conventional & alternative. I could not put this book down, & totally enjoyed the author's personal narrative, his wry sense of humor, & his articulate voice. Absolutely amazing that he survived his brain cancer 20+ yrs via a "cocktail" of prescription and OTC drugs, along with a couple rounds of chemo. This book reinforces my belief in alternative medicine's promise, & I believe would be of high value to any newly-diagnosed patient looking for alternatives to the decades-old "slash & burn" conventional treatments.

---

## Why Shop on Desertcart?

- 🛒 **Trusted by 1.3+ Million Shoppers** — Serving international shoppers since 2016
- 🌍 **Shop Globally** — Access 737+ million products across 21 categories
- 💰 **No Hidden Fees** — All customs, duties, and taxes included in the price
- 🔄 **15-Day Free Returns** — Hassle-free returns (30 days for PRO members)
- 🔒 **Secure Payments** — Trusted payment options with buyer protection
- ⭐ **TrustPilot Rated 4.5/5** — Based on 8,000+ happy customer reviews

**Shop now:** [https://www.desertcart.us/products/7931048-surviving-terminal-cancer-clinical-trials-drug-cocktails-and-other-treatments](https://www.desertcart.us/products/7931048-surviving-terminal-cancer-clinical-trials-drug-cocktails-and-other-treatments)

---

*Product available on Desertcart United States of America*
*Store origin: US*
*Last updated: 2026-03-22*